The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Socioeconomic aspects of incretin-based therapy
Open accessAbstract
Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have demonstrated cardiovascular benefits in people with type 2 diabetes. However, socioeconomic disparities in their uptake may constrain the collective advantages offered by these medications to the broader population. In this review we examine the socioeconomic disparities in the utilisation of incretin-based therapies and discuss strategies to address these inequalities. Based on real-world evidence, the uptake of GLP-1 RAs is reduced in people who live in socioeconomically disadvantaged areas, have low income and education level, or belong to racial/ethnic minorities, even though these individuals have a greater burden of type 2 diabetes and cardiovascular disease. Contributing factors include suboptimal health insurance coverage, limited accessibility to incretin-based therapies, financial constraints, low health literacy and physician–patient barriers such as provider bias. Advocating for a reduction in the price of GLP-1 RAs is a pivotal initial step to enhance their affordability among lower socioeconomic groups and improve their value-for-money from a societal perspective. By implementing cost-effective strategies, healthcare systems can amplify the societal benefits of incretin-based therapies, alongside measures that include maximising treatment benefits in specific subpopulations while minimising harms in vulnerable individuals, increasing accessibility, enhancing health literacy and overcoming physician–patient barriers. A collaborative approach between governments, pharmaceutical companies, healthcare providers and people with diabetes is necessary for the effective implementation of these strategies to enhance the overall societal benefits of incretin-based therapies. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Without insurance coverage, many initiators of semaglutide and tirzepatide cannot afford long‐term treatment, 28 which is concerning given the higher obesity burden and treatment needs among those with lower socio‐economic status, mental illness, obesity‐related comorbidities and younger age. 39 , 40 , 41”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In everyday clinical care, users are more likely to skip doses, take less than the prescribed amount, or not fill their prescriptions at all, due to factors like suboptimal insurance coverage, financial constraints, periodically limited drug accessibility, side effects and physician–patient barriers. 28”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As recently reviewed, 28 lower education, lower income, older age and non‐White race are associated with 10%–50% lower odds of receiving GLP‐1RA versus other diabetes therapies in real‐world patients with T2DM.”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In everyday clinical care, users are more likely to skip doses, take less than the prescribed amount, or not fill their prescriptions at all, due to factors like suboptimal insurance coverage, financial constraints, periodically limited drug accessibility, side effects and physician–patient barriers. 28”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Observational data suggest a notable under-utilisation of GLP-1 RAs among individuals in lower socioeconomic groups, primarily due to the high cost of these medications, highlighting the disparity in access to effective diabetes treatments based on socioeconomic factors [63]”
From Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials (2024) · cites this paper as [63]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health literacy and public health: A systematic review and integration of definitions and models
Sørensen, K., Van den Broucke, S., Fullam, J., Doyle, G., Pelikan, J., Slonska, Z., Brand, H., & (HLS-EU) Consortium Health Literacy Project European (2012) · BMC Public Health · doi:10.1186/1471-2458-12-80 · Cited by 6,213
Indicators of socioeconomic position (part 1): Figure 1
Galobardes, B., Shaw, M., Lawlor, D. A., Lynch, J. W., & Davey Smith, G. (2006) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2004.023531 · Cited by 2,867 · cited 2×
“Socioeconomic status refers to the social and economic factors that influence what position individuals or groups hold within the structure of a society [1].”
BackgroundHow Structural Racism Works — Racist Policies as a Root Cause of U.S. Racial Health Inequities
Bailey, Z. D., Feldman, J. M., & Bassett, M. T. (2021) · New England Journal of Medicine · doi:10.1056/nejmms2025396 · Cited by 1,598
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis
Agardh, E., Allebeck, P., Hallqvist, J., Moradi, T., & Sidorchuk, A. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr029 · Cited by 1,014
Stormacq, C., Van den Broucke, S., & Wosinski, J. (2019) · Health Promotion International · doi:10.1093/heapro/day062 · Cited by 928 · cited 2×
“The disparity in use of GLP-1 RAs between high-income and low-income people with type 2 diabetes is further exacerbated by the ongoing global shortage of semaglutide and dulaglutide, partially driven by increased off-label use of these drugs for weight loss [37, 38].”
BackgroundButler, D. C., Petterson, S., Phillips, R. L., & Bazemore, A. W. (2013) · Health Services Research · doi:10.1111/j.1475-6773.2012.01449.x · Cited by 689 · cited 2×
“Sociodemographic factors Sociodemographic factors such as race/ethnicity and age can also influence the uptake of newer medications and have been taken into consideration in the development of socioeconomic indexes [27].”
BackgroundDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Brown, A. F. (2004) · Epidemiologic Reviews · doi:10.1093/epirev/mxh002 · Cited by 606 · cited 3×
“1 3 [3, 7] and is associated with increased mortality and risk for cardiovascular complications [2, 8–13].”
BackgroundMagnani, J. W., Mujahid, M. S., Aronow, H. D., Cené, C. W., Dickson, V. V., Havranek, E., Morgenstern, L. B., Paasche-Orlow, M. K., Pollak, A., Willey, J. Z., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000579 · Cited by 581
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024) · Diabetologia · doi:10.1007/s00125-024-06144-1 · Cited by 102
“…though s.c. tirzepatide has been suggested to be cost-effective compared with s.c. semaglutide in the USA [64], cost-effectiveness analyses conducted in low-, middle-and high-income countries have demonstrated that GLP-1 RAs are not cost-effective compared with other glucose-lowering drugs [63].”
Self-citationCardiovascular-kidney-metabolic syndrome: A step toward multidisciplinary and inclusive care
Claudel, S. E., & Verma, A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.015 · Cited by 81
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 93
“Value-based pricing, patient support programs, and cooperation among healthcare providers, payers, and legislators may help overcome these barriers and increase access to promising drugs [111,114].”
BackgroundAhmed, I. A. B. (2024) · Journal of Obesity · doi:10.1155/2024/8056440 · Cited by 52
“…cessation of discontinuation of GLP1-RAs or even unawareness of such therapies include in-adequate health insurance coverage, restricted access to incretin-based treatments, budgetary limitations, in-sufcient health literacy, and obstacles between doctors and patients, such as provider bias [16].”
Metadata
- Authors
- Karagiannis, T., Bekiari, E., & Tsapas, A.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Venue
- Diabetologia
- Published
- 2023-07-12
- Volume
- 66
- Issue
- 10
- Pages
- 1859-1868
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC10474181
- OpenAlex
- W4383893957
- Semantic Scholar
- 7c7f4e8ec6dd829ffa2357a4b0b49c1dd50e9db4
- Cited by
- 91
- References
- 71
- Citations by year
- 2026: 37 · 2025: 27 · 2024: 23 · 2023: 4
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Aristotle University of Thessaloniki
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Health › Health disparities and outcomes
- Keywords
- incretin-based therapy, GLP-1 receptor agonists, type 2 diabetes, socioeconomic disparities, health disparities, drug affordability, health insurance coverage, health literacy, provider bias, racial and ethnic minorities, cardiovascular benefits, drug pricing, health care access
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Socioeconomic Factors, Glucagon-Like Peptide 1, Incretins, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Socioeconomic aspects of incretin-based therapy. https://app.cochat.ai/papers/10.1007/s00125-023-05962-z
- The paper
- Karagiannis, T., Bekiari, E., & Tsapas, A. (2023). Socioeconomic aspects of incretin-based therapy. Diabetologia. https://doi.org/10.1007/s00125-023-05962-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.